The company started in
Oss,
Netherlands in 1923 with the extraction of insulin from bovine pancreata, and porcine insulin extraction in 1930. In January 2005, the company became a part of
Organon, one of its sister companies in the
Akzo Nobel pharma group. Along with its sister companies Organon and
Intervet were sold to
Schering-Plough in March 2007 by
Akzo Nobel. Following the mergers of Schering-Plough with
Merck & Co. (MSD) on March 9, 2009, the company temporarily became part of the MSD Nutritionals products company, belonging to the MSD group. In 2009, MSD acquired the biologics business of the
Avecia group, which consists of the Billingham, UK site. Combined, the Merck/MSD BioManufacturing Network was formed by the combination of Avecia Biologics and Diosynth Biotechnology offering contract manufacturing services. In April 2011, the Merck BioManufacturing Network was sold to
Fujifilm, forming Fujifilm Diosynth Biotechnologies. For most of the company's history, Diosynth manufactured biochemical substances and fine chemicals, with pharmaceutical raw materials coming largely from either animal origin or chemical intermediates. Under Fujifilm, it no longer focuses on small molecules, but instead develops processes for and mass manufactures biologics (e.g., proteins and mRNA). On December 18, 2014, Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutic Technologies in College Station, TX, which became Fujifilm Diosynth Biotechnologies Texas. In 2019, Fujifilm acquired
Biogen's Denmark manufacturing facility in
Hillerød for $890 million. In March 2020, Fujifilm Diosynth Biotechnologies named Martin Meeson the company's new CEO. He took over from Steve Bagshaw who was set to retire and became a non-executive chairman. In June 2023, Lars Petersen succeeded Martin Meeson as the new CEO. In March 2021, the company announced that it had selected
Holly Springs, North Carolina, located near its existing operations in Morrisville, for a $2 billion investment to establish a new large-scale cell culture production site, which is expected to be operational in 2025 and create 725 new jobs by the end of 2028. The company plans to install 8 x 20,000L bioreactors at the facility and plan for the ability to add an additional 24 x 20,000L bioreactors, as well as production lines for large scale automated fill and finish, labeling, and packaging services. ==References==